诺沃·诺迪斯克正在投资4.32亿欧元,以扩大爱尔兰口服糖尿病和减重药物生产,创造600个就业机会,到2028年增加全球供应。 Novo Nordisk is investing €432 million to expand oral diabetes and weight-loss drug production in Ireland, creating 600 jobs and boosting global supply by 2028.

Novo Nordisk正在其爱尔兰阿特隆投资4.32亿欧元,该设施旨在扩大口服减重和糖尿病药物的生产,包括GLP-1治疗。 Novo Nordisk is investing €432 million in its Athlone, Ireland, facility to expand production of oral weight-loss and diabetes medications, including GLP-1 treatments. 这一升级立即开始,将提高美国以外的全球供应能力,创造多达600个建筑工作岗位,并加强爱尔兰作为生命科学枢纽的作用。 The upgrade, which began immediately, will enhance global supply capacity outside the U.S., create up to 600 construction jobs, and strengthen Ireland’s role as a life sciences hub. 预计将在2028年完成。 Completion is expected by 2028.